📄 📄 Our molnupiravir work is now out after peer-review! We definitively demonstrate that molnupiravir has resulted in viable SARS-CoV-2 viruses with significant numbers of mutations, in some cases with onwards transmission of mutated viruses. nature.com/articles/s4158…

Fascinating work on "generic" antigen design nature.com/articles/s4155… Great to see my former post-doc advisor Simon Frost continuing to contribute to innovative projects.

Great study. Clever genomic forensics. Molnuipravir: playing generic roulette.

#UthankU giveaway! RT for a chance to win a signed King Julian Carranza jersey! #DOOP

This seems highly apropos w.r.t to the posts in my feed regarding the revised Bayes Factors in science.org/doi/10.1126/sc…

I like the revised NIH review criteria (nature.com/articles/d4158…). Now please revise grant budget caps to reflect the reality that 250K in 2023 is worth ~50% compared to the 1990s (usinflationcalculator.com)

You can now run HyPhy entirely in your browser thanks to Emscripten, Observable and biowasm (Robert Aboukhalil). Simple example in observablehq.com/@spond/hyphy-b…

AUTO-TUNE: SELECTING THE DISTANCE THRESHOLD FOR INFERRING HIV TRANSMISSION CLUSTERS biorxiv.org/cgi/content/sh… #biorxiv_bioinfo

Oops. On the day the new 2024 highly cited researcher list is released, clarivate website crashes. How 1990s.

The 15% indirect cost cap by the NIH is denotating a nuke under the current business model of many US schools, especially medical schools. Major changes incoming. Maybe relaized savings will translate to larger grant budgets/better success rates, but I not holding my breath.